FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324740432> ?p ?o ?g. }

• W2324740432 abstract "In the United States alone this year approximately 3,500 people will be diagnosed with leiomyosarcoma (LMS), a rare, malignant soft tissue cancer derived from smooth muscle cells, and about 36% will perish from this disease, despite the current medical interventions of surgery, radio- and chemotherapy. Epidemiological studies have indicated that the risk of many types of epithelial cancer including breast, prostate, colorectal, and endometrial cancer is increased in night-shift workers. These individuals experience circadian disruption in response to ocular exposure to light at night, which suppresses the nocturnal circadian production of melatonin by the pineal gland. In previous studies, we demonstrated that human LMS perfused with rodent donor blood containing physiological nocturnal levels of melatonin (1nM) showed a complete inhibition of LA uptake, 13-HODE release, and marked reduction in tumor cAMP levels and [ 3 H]thymidine incorporation into tumor DNA. Here we showed the in vivo effects of a physiological, nocturnal concentration of melatonin on tumor proliferative activity mediated via aerobic glycolysis (Warburg effect) and LA metabolic signaling in tissue-isolated LMS xenografts perfused in situ in nude rats with human donor blood. Following tumor implantation, LMS xenografts exhibited latency-to-onset and growth rates that were 22 days and 0.21 ± 0.04 g/day, respectively; mean tumor weights were 5.1 ± 0.2 g (n = 72). The tissue-isolated human LMS xenografts in nude rats perfused in situ for 60 min with human donor blood containing melatonin resulted in a significant reduction in tumor aerobic glycolysis that included a 30-50% reduction in glucose uptake, lactate release, O 2 uptake and CO 2 production. Additionally, melatonin induced a complete inhibition of LA uptake, 13-HODE release, ERK 1/2, Akt, GSK3β (Ser 9 ), and NF-kB (p65) phosphorylation, as well as significant reductions in tumor cAMP levels, DNA content and [ 3 H]thymidine incorporation into tumor DNA. Addition of the non-selective MT 1 /MT 2 melatonin antagonist S20928 (1 μM) completely reversed the inhibitory effects of melatonin on aerobic glycolysis, LA metabolic signaling and proliferative activity in LMS xenografts. Moreover, melatonin at physiological concentrations (1 nM) induced a 30-50% inhibition in cell proliferation in culture, and suppressed cell invasion by 30% in the transwell assay. These results demonstrate that in human LMS nocturnal melatonin levels directly and rapidly inhibit tumor growth activity and invasion via suppression of the Warburg effect and LA metabolic and other related signaling mechanisms. An understanding of this novel signaling pathway for the control of aerobic glycolysis and LA metabolism in human leiomyosarcoma could lead to new circadian-based approaches for cancer therapy and/or prevention of rare but highly aggressive mesenchymally-derived solid tumors. Citation Format: Lulu Mao, Robert T. Dauchy, Erin M. Dauchy, Melissa A. Wren, Samantha D. Zeringue, Victoria P. Belancio, David E. Blask, Steven M. Hill. Melatonin inhibits aerobic glycolysis (Warburg effect) and fatty acid metabolic signaling in human leiomyosarcoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5423. doi:10.1158/1538-7445.AM2013-5423 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend." @default.
• W2324740432 created "2016-06-24" @default.
• W2324740432 creator A5003731794 @default.
• W2324740432 creator A5016402426 @default.
• W2324740432 creator A5020223547 @default.
• W2324740432 creator A5037460127 @default.
• W2324740432 creator A5043142422 @default.
• W2324740432 creator A5046305632 @default.
• W2324740432 creator A5071281736 @default.
• W2324740432 creator A5087047463 @default.
• W2324740432 date "2013-04-15" @default.
• W2324740432 modified "2023-09-27" @default.
• W2324740432 title "Abstract 5423: Melatonin inhibits aerobic glycolysis (Warburg effect) and fatty acid metabolic signaling in human leiomyosarcoma." @default.
• W2324740432 doi "https://doi.org/10.1158/1538-7445.am2013-5423" @default.
• W2324740432 hasPublicationYear "2013" @default.
• W2324740432 type Work @default.
• W2324740432 sameAs 2324740432 @default.
• W2324740432 citedByCount "0" @default.
• W2324740432 crossrefType "proceedings-article" @default.
• W2324740432 hasAuthorship W2324740432A5003731794 @default.
• W2324740432 hasAuthorship W2324740432A5016402426 @default.
• W2324740432 hasAuthorship W2324740432A5020223547 @default.
• W2324740432 hasAuthorship W2324740432A5037460127 @default.
• W2324740432 hasAuthorship W2324740432A5043142422 @default.
• W2324740432 hasAuthorship W2324740432A5046305632 @default.
• W2324740432 hasAuthorship W2324740432A5071281736 @default.
• W2324740432 hasAuthorship W2324740432A5087047463 @default.
• W2324740432 hasConcept C109156525 @default.
• W2324740432 hasConcept C121608353 @default.
• W2324740432 hasConcept C126322002 @default.
• W2324740432 hasConcept C134018914 @default.
• W2324740432 hasConcept C142724271 @default.
• W2324740432 hasConcept C150903083 @default.
• W2324740432 hasConcept C207001950 @default.
• W2324740432 hasConcept C2777532014 @default.
• W2324740432 hasConcept C2778182776 @default.
• W2324740432 hasConcept C2780192828 @default.
• W2324740432 hasConcept C502942594 @default.
• W2324740432 hasConcept C55885012 @default.
• W2324740432 hasConcept C71924100 @default.
• W2324740432 hasConcept C86803240 @default.
• W2324740432 hasConcept C96232424 @default.
• W2324740432 hasConceptScore W2324740432C109156525 @default.
• W2324740432 hasConceptScore W2324740432C121608353 @default.
• W2324740432 hasConceptScore W2324740432C126322002 @default.
• W2324740432 hasConceptScore W2324740432C134018914 @default.
• W2324740432 hasConceptScore W2324740432C142724271 @default.
• W2324740432 hasConceptScore W2324740432C150903083 @default.
• W2324740432 hasConceptScore W2324740432C207001950 @default.
• W2324740432 hasConceptScore W2324740432C2777532014 @default.
• W2324740432 hasConceptScore W2324740432C2778182776 @default.
• W2324740432 hasConceptScore W2324740432C2780192828 @default.
• W2324740432 hasConceptScore W2324740432C502942594 @default.
• W2324740432 hasConceptScore W2324740432C55885012 @default.
• W2324740432 hasConceptScore W2324740432C71924100 @default.
• W2324740432 hasConceptScore W2324740432C86803240 @default.
• W2324740432 hasConceptScore W2324740432C96232424 @default.
• W2324740432 hasLocation W23247404321 @default.
• W2324740432 hasOpenAccess W2324740432 @default.
• W2324740432 hasPrimaryLocation W23247404321 @default.
• W2324740432 hasRelatedWork W1570111108 @default.
• W2324740432 hasRelatedWork W1986206057 @default.
• W2324740432 hasRelatedWork W1991621680 @default.
• W2324740432 hasRelatedWork W2045987911 @default.
• W2324740432 hasRelatedWork W2048678284 @default.
• W2324740432 hasRelatedWork W2086841409 @default.
• W2324740432 hasRelatedWork W2093169444 @default.
• W2324740432 hasRelatedWork W2123328403 @default.
• W2324740432 hasRelatedWork W2147917643 @default.
• W2324740432 hasRelatedWork W2150497617 @default.
• W2324740432 hasRelatedWork W2155386683 @default.
• W2324740432 hasRelatedWork W2180511011 @default.
• W2324740432 hasRelatedWork W2324241785 @default.
• W2324740432 hasRelatedWork W2407351686 @default.
• W2324740432 hasRelatedWork W2580006520 @default.
• W2324740432 hasRelatedWork W2594811863 @default.
• W2324740432 hasRelatedWork W2887805349 @default.
• W2324740432 hasRelatedWork W2900455338 @default.
• W2324740432 hasRelatedWork W2996231111 @default.
• W2324740432 hasRelatedWork W3186879400 @default.
• W2324740432 isParatext "false" @default.
• W2324740432 isRetracted "false" @default.
• W2324740432 magId "2324740432" @default.
• W2324740432 workType "article" @default.